Immix Biopharma (Nasdaq: IMMX)

Our immune system works every day to recognize and eliminate disease. But in AL Amyloidosis, diseased cells can evade the immune response, making treatment challenging. NXC-201 is an investigational CAR-T therapy developed by Immix Biopharma that uses a patient’s own immune cells, modified with proprietary technology, to better recognize and target these diseased cells. Early clinical studies in Relapsed/Refractory AL Amyloidosis show promising overall response rates. NXC-201 is currently being evaluated in ongoing trials to understand its full potential and safety. #NXC201 #CAR_T #ALAmyloidosis #Immunotherapy #ClinicalTrials #IMMX

Cleveland Clinic recently profiled NEXICART-2 as the first U.S. clinical trial investigating a CAR-T therapy in Relapsed/Refractory AL Amyloidosis. In the article, they highlight: ✔️ 70% complete response rate by Day 7 ✔️ No observed neurotoxicity ✔️ Only low-grade CRS ✔️ No relapses observed at time of reporting We're grateful to see this pioneering study gaining recognition from leading institutions. NXC-201 is an investigational therapy and has not been approved by the FDA. Read the full article: https://lnkd.in/e6QsURNP #ALAmyloidosis #CAR_T #ClinicalResearch #NXC201 #ClevelandClinic #Hematology #ClinicalTrial #IMMX

Immix Biopharma is committed to advancing investigational cell therapies for patients with AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that filters out non-specific activation. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design We invite you to follow our progress as we work toward expanding treatment options and developing a potential BLA submission in this area. #ImmixBiopharma #NXC201 #ALAmyloidosis #CellTherapy #ClinicalTrials #Biotech #IMMX

Immix Biopharma announces a class-leading safety profile for its investigational CAR-T therapy, NXC-201, as demonstrated by the absence of neurotoxicity of any grade in low-volume disease to date. These safety results support ongoing clinical development in the NEXICART-2 trial for relapsed/refractory AL Amyloidosis and lay the groundwork for potential future indication expansion. We remain focused on completing NEXICART-2 and advancing toward a potential Biologics License Application (BLA) submission. Read the full press release and access ASCO 2025 publications and our KOL webcast here: https://lnkd.in/eXmTVss7 #ImmixBiopharma #NXC201 #ALAmyloidosis #CellTherapy #ClinicalTrials #ASCO2025 #Biotech #IMMX

Proteins in our bodies fold into precise shapes to function properly. However, when this folding goes awry, it can cause diseases like AL Amyloidosis. Thanks to advances in science, researchers are discovering new methods to identify and address protein misfolding issues earlier, paving the way for more effective and targeted treatments. At Immix Biopharma, we’re proud to be at the forefront of developing innovative therapies designed to work in harmony with the body, bringing hope to patients facing these challenging conditions. #ALAmyloidosis #BiotechInnovation #ImmixBiopharma #IMMX

We’re proud to announce accelerated progress in the U.S. NEXICART-2 clinical trial for patients with relapsed/refractory AL Amyloidosis. The trial now includes 18 clinical sites nationwide — a significant milestone as we continue advancing toward a potential Biologics License Application (BLA) submission for NXC-201 in this previously unaddressed orphan indication. Access the ASCO publication, video, and KOL webcast here: https://lnkd.in/e6qiXHqZ #ImmixBiopharma #NEXICART2 #ALAmyloidosis #ClinicalTrials #CellTherapy #Biotech #ASCO2025 #IMMX

Early data from the Phase 1/2 NEXICART-2 trial indicate that NXC-201, a BCMA-targeted CAR T-cell therapy, was generally well tolerated in patients with relapsed or refractory AL Amyloidosis. All patients experienced hematologic responses, with 70% complete responses , and investigators observed manageable safety profiles, including low-grade cytokine release syndrome and no neurotoxicity. Read more: https://lnkd.in/ePdpiGad #ALAmyloidosis #CARTCellTherapy #ClinicalTrial #ImmixBiopharma #NXC201 #IMMX

At Immix Biopharma, we are developing NXC-201, an investigational CAR-T cell therapy currently in clinical trials for AL Amyloidosis and immune-mediated diseases. NXC-201 targets plasma cells linked to the production of misfolded proteins and antibodies that may contribute to organ damage and immune dysfunction. Learn more about the science behind NXC-201: https://lnkd.in/ed_86frm #ALAmyloidosis #CARTCellTherapy #ClinicalDevelopment #Biotech #ImmuneMediatedDiseases #IMMX

Early clinical data presented at ASCO 2025 by Dr. Heather Landau, MD (MSK), highlight the potential of BCMA-targeted CAR T cell therapy (NXC-201) in patients with relapsed or refractory AL Amyloidosis. In a phase 1 investigator-led trial: • All patients had normalized free light chain levels within 7–15 days • 8/9 tested patients showed no detectable minimal residual disease after 25 days • No relapses observed to date • Side effects were manageable These results are from an ongoing clinical trial and have not yet been reviewed or approved by the FDA. #ALAmyloidosis #CAR_T #Immunotherapy #Biotech #ClinicalTrials #ImmixBiopharma #IMMX

At the 2025 ASCO Annual Meeting, Dr. Shahzad Raza of the Cleveland Clinic presented early data from the NEXICART-2 trial, the first U.S. study of CAR-T therapy in relapsed/refractory AL Amyloidosis. The trial is evaluating NXC-201, an autologous BCMA-targeted CAR-T cell therapy, studying its safety and efficacy in this challenging patient population. In this interview, Dr. Raza discusses the trial's design, the significance of these findings, and the potential impact on treatment options for patients with relapsed/refractory AL amyloidosis. Watch the full interview to learn more about this groundbreaking research: https://lnkd.in/e9YcnM9Q #ALAmyloidosis #CARTCellTherapy #ClinicalResearch #ASCO2025 #IMMX #NXC201